🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. ARO-ANG 3 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  2. ARO-DM1 Intravenous (IV) Infusion

    Arrowhead Pharmaceuticals Ireland Limited

    Myotonic Dystrophy 1

    phase 2 small molecule active

    1 trial

  3. ARO-DUX4 for Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Facio-Scapulo-Humeral Dystrophy

    phase 2 small molecule active

    1 trial

  4. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  5. ARO-MMP7 Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  6. ARQ-151 cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial

  7. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    2 trials

  8. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    1 trial

  9. ARQ-154

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  10. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Vitiligo

    phase 2 small molecule terminated

    1 trial

  11. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Chronic Hand Eczema

    phase 2 small molecule completed

    1 trial

  12. ART27.13, Placebo, ART27.13

    ARTELO BIOSCIENCES, INC.

    Cancer Anorexia

    phase 2 small molecule active

    1 trial

  13. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  14. AS01 adjuvant (0.5 mL intramuscular)

    Hospital Authority, Hong Kong

    Immune System Responses and Trained Immunity After AS01 Administration

    phase 2 mab active

    1 trial

  15. ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib

    Novartis Pharmaceuticals

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  16. ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Astellas Pharma GmbH

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  17. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. ASP8951, Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Astellas Pharma GmbH

    Advanced cancer of the stomach or the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  19. ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 2 small molecule active

    1 trial

  20. ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  21. ASTX727, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy

    phase 2 small molecule active

    1 trial

  22. AT-1501

    Eledon Pharmaceuticals

    Kidney Transplant Rejection

    phase 2 small molecule active

    2 trials

  23. AT-1501

    Eledon Pharmaceuticals

    Prevention of Rejection in Kidney Transplant

    phase 2 small molecule active

    1 trial

  24. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources